Back to investors
DR

David Rubenstein

Co-Founder

special-situationCarlyle Group Inc. →
Fund
Carlyle Group Inc.
Carlyle Group Inc.
AUM
$10B
Q2 2026
Filings
14
13F history
David Rubenstein’s latest 13F filing shows a portfolio built around special-situation bets, but the data is thin: no fund name, no AUM, and no top holdings were reported for the quarter. That absence is itself a signal. Rubenstein, a co-founder of one of the largest private equity firms, has long used his personal account to take concentrated, event-driven positions that do not fit a standard growth or value mandate. Without a disclosed holding list, the filing offers no fresh evidence of a new thesis, no shift in sector weight, and no clue about whether he is adding to a distressed energy name or trimming a legacy media stake. What the filing does confirm is that Rubenstein’s public equity footprint remains a small, opportunistic sideline relative to his private market work. His style has historically favored special situations: spin-offs, restructuring plays, and companies with activist catalysts. Peers with similar backgrounds often run their personal 13Fs as a mirror of their firm’s strategy, but Rubenstein has diverged by keeping his public book lean and idiosyncratic. The lack of a fund name and AUM in the latest report suggests he is not managing third-party capital through this vehicle, which frees him from benchmark pressure and lets him hold positions for longer than a typical hedge fund. The practical takeaway for readers is limited by the filing’s incompleteness. Rubenstein’s 13F is a trailing snapshot, and an empty top-holdings field means the most recent moves are invisible. Investors tracking him should wait for a subsequent filing that lists actual positions before drawing conclusions about his current conviction. Until then, the only defensible statement is that his public portfolio remains a minor, special-situation appendage to a much larger private investment operation.

AI-assisted summary

13F portfolio value

Disclosed portfolio value across 14 quarters of Carlyle Group Inc. filings.

Show data table
PeriodPortfolio value
Q1 2023$3.4B
Q2 2023$2.8B
Q3 2023$2.3B
Q4 2023$2.1B
Q1 2024$1.6B
Q2 2024$1.1B
Q3 2024$954.2M
Q4 2024$4.1B
Q1 2025$3.8B
Q2 2025$5B
Q3 2025$4.3B
Q4 2025$13.6B
Q1 2026$10.6B
Q2 2026$10B

Current holdings

Top 15 positions as of Q2 2026, from Carlyle Group Inc.'s latest 13F.

View all positions →
M

Medline Inc

Unchanged
Value
$7.4B
Shares
187.08M
% Port
73.78%
S

Standardaero Inc

Unchanged
Value
$2.5B
Shares
84.59M
% Port
25.30%
P

Phathom Pharmaceuticals Inc

Unchanged
Value
$37.9M
Shares
3.50M
% Port
0.38%
I

Invitation Homes Inc

-0.2%
Value
$20M
Shares
662.9K
% Port
0.20%
P

Pony Ai Inc

Unchanged
Value
$16.4M
Shares
2.36M
% Port
0.16%
G

Getty Images Holdings Inc

Unchanged
Value
$5.4M
Shares
6.23M
% Port
0.05%
?
7.N/A

Spruce Biosciences Inc

Unchanged
Value
$2.1M
Shares
38.6K
% Port
0.02%
S

SunPower Inc

+441.1%
Value
$1.6M
Shares
2.34M
% Port
0.02%
A

Adicet Bio Inc

Unchanged
Value
$1.6M
Shares
184.3K
% Port
0.02%
F

Forward Air Corp

Unchanged
Value
$1.4M
Shares
107.2K
% Port
0.01%
O

Onkure Therapeutics Inc

Unchanged
Value
$1.2M
Shares
269.9K
% Port
0.01%
L

Krispy Kreme Inc

Unchanged
Value
$1.2M
Shares
340.7K
% Port
0.01%
Q

Q32 Bio Inc

-94.5%
Value
$769K
Shares
60.4K
% Port
0.01%
R

Riley Exploration Permian In

Value
$530K
Shares
16.1K
% Port
0.01%
N

Nebius Group N.V.

Value
$510K
Shares
1.8K
% Port
0.01%

Explore

Photo: Maryland GovPics · CC BY 2.0